Treatment of complex regional pain syndrome type I with oral phenoxybenzamine: Rationale and case reports

Pain Practice

Volumn 8, Issue 2, 2008, Pages 125-132

  Inchiosa Jr , Mario A ^a   Kizelshteyn, Grigory ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Complex regional pain syndrome type I; Complex regional pain syndrome type II; Pharmacologic action; Sympathetic blocking agents; Therapeutics

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN; CODYDRAMOL; CORTISONE; GABAPENTIN; MELOXICAM; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PHENOXYBENZAMINE;

ACUPUNCTURE; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; DISEASE COURSE; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FIBROMYALGIA; HALLUX VALGUS; HUMAN; JOINT STIFFNESS; NOSE CONGESTION; PHYSIOTHERAPY; SYMPTOM; VISUAL ANALOG SCALE; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; FEMALE; HUMANS; MIDDLE AGED; PHENOXYBENZAMINE; REFLEX SYMPATHETIC DYSTROPHY; VASODILATOR AGENTS;

EID: 41249102292     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2007.00170.x     Document Type: Article

References (40)

1. Stanton-Hicks M, Jänig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: Changing concepts and taxonomy. Pain. 1995; 63: 127-133.
2. Schwartzman RJ, Alexander GM, Grothusen J. Pathophysiology of complex regional pain syndrome. Expert Rev Neurother. 2006; 6: 669-681.
3. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd ed. Seattle: IASP Press; 1994: 40-43.
4. Albrecht PJ, Hines S, Eisenberg E, et al. Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. Pain. 2006; 120: 244-266.
5. Oaklander AL, Rissmiller JG, Gelman LB, Zheng L, Chang Y, Gott R. Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain. 2006; 120: 235-243.
6. Jänig W, Baron R. Is CRPS I a neuropathic pain syndrome? Pain. 2006; 120: 227-229.
7. Ghostine SY, Comair YG, Turner DM, Kassell NF, Azar CG. Phenoxybenzamine in the treatment of causalgia. Report of 40 cases. J Neurosurg. 1984; 60: 1263-1268.
8. Lefkoe TP, Cardenas DD. Reflex sympathetic dystrophy of the lower extremity in tetraplegia: Case report. Spinal Cord. 1996; 34: 239-242.
9. Muizelaar JP, Kleyer M, Hertogs IA, DeLange DC. Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): Management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients. Clin Neurol Neurosurg. 1997; 99: 26-30.
10. Westfall TC, Westfall DP. Adrenergic Agonists and Antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's, the Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill; 2006: 267-268.
11. Hamilton C, Dalrymple H, Reid J. Recovery in vivo and in vitro of alpha-adrenoceptor responses and radioligand binding after phenoxybenzamine. J Cardiovasc Pharmacol. 1982; 4(suppl 1): S125-S128.
12. Jänig W, Baron R. Complex regional pain syndrome: Mystery explained? Lancet Neurol. 2003; 2: 687-697.
13. Malik VK, Inchiosa MA Jr, Mustafa K, Sanapati MR, Pimentel MC Jr, Frost EA. Intravenous regional phenoxybenzamine in the treatment of reflex sympathetic dystrophy. Anesthesiology. 1998; 88: 823-827.
14. Maleki J, LeBel AA, Bennett GJ, Schwartzman RJ. Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). Pain. 2000; 88: 259-266.
15. Forss N, Kirveskari E, Gockel M. Mirror-like spread of chronic pain. Neurology. 2005; 65: 748-750.
16. Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med. 2007; 8: 326-331.
17. Drummond PD, Finch PM, Skipworth S, Blockey P. Pain increases during sympathetic arousal in patients with complex regional pain syndrome. Neurology. 2001; 57: 1296-1303.
18. Singh B, Moodley J, Shaik AS, Robbs JV. Sympathectomy for complex regional pain syndrome. J Vasc Surg. 2003; 37: 508-511.
19. Torebjork E, Wahren L, Wallin G, Hallin R, Koltzenburg M. Noradrenaline-evoked pain in neuralgia. Pain. 1995; 63: 11-20.
20. Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic post-ischemia pain (CPIP): A novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. Pain. 2004; 112: 94-105.
21. Baron R, Maier C. Reflex sympathetic dystrophy: Skin blood flow, sympathetic vasoconstrictor reflexes and pain before and after surgical sympathectomy. Pain. 1996; 67: 317-326.
22. Drummond PD, Skipworth S, Finch PM. alpha 1-adrenoceptors in normal and hyperalgesic human skin. Clin Sci (Lond). 1996; 91: 73-77.
23. Wasner G, Schattschneider J, Heckmann K, Maier C, Baron R. Vascular abnormalities in reflex sympathetic dystrophy (CRPS I): Mechanisms and diagnostic value. Brain. 2001; 124: 587-599.
24. Baron R, Schattschneider J, Binder A, Siebrecht D, Wasner G. Relation between sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional pain syndromes: A case-control study. Lancet. 2002; 359: 1655-1660.
25. Arner S. Intravenous phentolamine test: Diagnostic and prognostic use in reflex sympathetic dystrophy. Pain. 1991; 46: 17-22.
26. Weber M, Birklein F, Neundorfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain. 2001; 91: 251-257.
27. Molina PE. Neurobiology of the stress response: Contribution of the sympathetic nervous system to the neuroimmune axis in traumatic injury. Shock. 2005; 24: 3-10.
28. Bertini R, Garattini S, Delgado R, Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunology. 1993; 79: 217-219.
29. Bloksma N, Hofhuis F, Benaissa-Trouw B, Willers J. Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade. Cancer Immunol Immunother. 1982; 14: 41-45.
30. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol. 1990; 145: 1430-1434.
31. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev. 2000; 52: 595-638.
32. Lo CJ, Garcia I, Cryer HG, Maier RV. Calcium and calmodulin regulate lipopolysaccharide-induced alveolar macrophage production of tumor necrosis factor and procoagulant activity. Arch Surg. 1996; 131: 44-50.
33. Earl CQ, Prozialeck WC, Weiss B. Interaction of alpha adrenergic antagonists with calmodulin. Life Sci. 1984; 35: 525-534.
34. Lukas TJ, Marshak DR, Watterson DM. Drug-protein interactions: Isolation and characterization of covalent adducts of phenoxybenzamine and calmodulin. Biochemistry. 1985; 24: 151-157.
35. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991; 173: 699-703.
36. Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med. 2001; 161: 2502-2503.
37. Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med. 2003; 163: 1487-1488.
38. Physicians' Desk Reference, 61 ed. Montvale, NJ: Thomson PDR; 2007.
39. USPDI, Vol. 1 Drug Information for the Health Care Professional, Vol. 2, Advice for the Patient. 27th ed. Greenwood Village, Coloradoa: Thomson MICROMEDEX; 2007.
40. Te AE. A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. Clin Ther. 2002; 24: 851-861.